Nanotheranostics and Precision Oncology
- 1st Edition - September 11, 2025
- Latest edition
- Editors: Ramish Riaz, Maria Shabbir, Yasmin Badshah, Abdullah Ahmad, Khushbukhat Khan
- Language: English
Nanotheranostics and Precision Oncology delves into the merging fields of cancer research and nanotechnology, offering a thorough review of the latest advancements in precis… Read more
Data Mining & ML
Unlock the cutting edge
Up to 20% on trusted resources. Build expertise with data mining, ML methods.
Description
Description
In addition, the book examines nanotheranostics' applications and mechanisms in cancer diagnosis and treatment, integrating them with precision oncology. It outlines the design, mechanism, and impact of nanoprecision medicine in cancer management. The final section considers the future of nanotheranostics in precision oncology and the challenges of translating these innovations from research to clinical practice. This comprehensive guide serves students, clinicians, researchers, and the pharmaceutical industry involved in nanomedicine, oncology, molecular biology, and precision medicine.
Key features
Key features
- Offers a comprehensive look at cancer biology and the genetic roots of oncogenesis
- Provides in-depth coverage of the latest in precision oncology and nanotheranostics, including development and clinical use
- Explores the integration of nanotechnology with precision medicine for creating individualized treatments
- Includes case studies and regulatory insights that guide pharmaceutical innovation and clinical practice
Readership
Readership
Table of contents
Table of contents
1. Oncogenesis: Genetic basis
Anum Chaudhry, Hania Shah and Shan e Zahra Sheikh
2. Hallmarks of cancer
Fizzah Abid and Mudassir Khan
3. Cancer stem cells and tumor microenvironment
Asma Areesh and Rimsha Sahr
4. Mechanisms underpinning invasion and metastasis
Suhail Razak, Sameen Zafar and Tayyaba Afsar
5. Drug resistance in cancer
Zarish Fatima, Tayaba Irfan, Maria Shabbir and Yasmin Badshah
Section II: Precision oncology
6. Introduction to precision medicine
Maryam Akmal and Iqra Mutiullah
7. Translational bioinformatics and precision medicine
Maaz Waseem
8. Proteomics, metabolomics, and precision medicine
Fizzah Abid and Ghulam Murtaza Kamal
9. Biomarkers and circulating DNAs as predictive molecular signatures
Momina Tariq and Amaara Niazi
10. Genomic strategies for precision medicine
Asma Latif, Farheen Zahid and Yasmin Badshah
11. Immunotherapy as a tool of precision medicine
Haipeng Tao, Rameesha Fareed, Robert Dalton, Richa Gupta, Anjali Chauhan, Ravi Kumar, Srabasti Sengupta, Chong Zhao, Meiqi Shi and Muhammad Abbas
12. Clinically approved and under trial drugs for precision oncology
Syeda Tahira Qousain Naqvi and Sana Khalid
Section III: Nanotheranostics
13. Introduction to nanotheranostics
Maisra Azhar Butt and Sobia Tabassum
14. Active and passive targeting of nanoparticles
Maisra Azhar Butt and Sobia Tabassum
15. Nanocontrasts, nanoprobes, and nanosensors in cancer diagnosis
Mushkbar Fatima, Laleen Saeed and Ramish Riaz
16. Nanoparticles as delivery vehicle for drugs and genes
Aleena Haqqi and Zeemal Seemab Amin
17. Nanoparticles for thermal ablation
Usama Masood, Tayyaba Hussain and Madeeha Chaudhry
Section IV: Designing nanotheranostics for precision medicine
18. Current status of nanotheranostics in precision medicine
Muhammad Abu Bakar Saddique, Muhammad Dawood Amjad, Huzaifa Tahir and Khired Sajid
19. Nano-immunotherapy
Aneela Mustafa and Amna Hafeez
20. Stimuli-responsive nanotheranostics for precision medicine
Sehrish Abbas and Bushra Uzair
21. Pharmacogenomics-based nanoprecision medicine
Sidrah Hafeez and Shafia Maryam
22. ADME of nanoprecision medicines: Understanding the pharmacokinetics and pharmacodynamics of nanoprecision medicines
Kaynat Iftekhar, Khired Sajid, Maria Rafiq and Mudassir Khan
Section V: Challenges and future potentials
23. Challenges in translation of nanoprecision medicine
Rimsha Ashraf, Tauqeer Hussain, Muhammad Summer and Shaukat Ali
24. Ethical and legal considerations in the use of nanotheranostics and precision medicine
Amna Naheed Khan and Erum Dilshad
25. Economic challenges in use of nanotheranostics and precision medicine
Areeba Ikram, Asma Rehman and Ramish Riaz
26. Biomarkers emerging in nanotheranostics and precision medicine
Tooba Khan, Zainab Nisar Qureshi, Amaara Niazi, Mahnoor Ejaz and Khushbukhat Khan
27. Panomics, artificial intelligence, and precision medicine
Mahnoor Basit, Momna Jamil, Rohma Jamil, Muhammad Haroon and Khushbukhat Khan
28. Nanotheranostics and precision medicine redefining the future of healthcare
Roomisa Anis, Muhammad Huzaifah Qureshi, Fatima Irfan and Seyyedha Abbas
Product details
Product details
- Edition: 1
- Latest edition
- Published: September 23, 2025
- Language: English
About the editors
About the editors
RR
Ramish Riaz
Dr. Ramish Riaz is an Assistant Professor and Head of Department, Medical Imaging Technology at Riphah International University. She completed her Ph.D. from NUST with a specialization in microbubble contrast agents. She has an M.Phil degree in Biotechnology with a specialization in cancer genetics. She is a graduate of Rawalpindi Medical University Imaging Technology Ramish worked on phase convertible nanodroplets as contrast agents and drug delivery agents during her PhD. Her major research interests include nanomedicine, drug delivery, and radiological contrast agents. She has multiple publications in the field of nanomedicine and wrote two Book Chapters on Cancer Genetics, & the Role of Nanomedicine in Cancer Therapy for Springer Nature.
MS
Maria Shabbir
Dr. Maria Shabbir is an Associate Professor at NUST with around 8 years of academic experience. She has PhD degree in cancer genetics from Quaid e Azam University and a Post-doc form the University of Wisconsin, USA. She has received multiple grants and have many publications in credit in the field of cancer genetics. Her research group aims to identify cancer genes, which are genes that when mutated contribute to cancer development by promoting tumor cell growth and by conferring upon a cancer cell the ability to evade the cell cycle and cell death checkpoints that would normally control their growth. I am also interested in the networks and pathways that contribute to tumor development and how cancer genes work together to promote tumor evolution.
YB
Yasmin Badshah
AA
Abdullah Ahmad
KK
Khushbukhat Khan
Simultaneously, Dr. Khan holds the esteemed position of Project Lead for oncology pre-clinical and clinical trials at Trials360, a distinguished subsidiary of Hayat Pharmaceutical Consulting located in California, USA. Her academic foundation includes a Ph.D. earned from the esteemed National University of Sciences and Technology (NUST), one of Asia's premier institutions.